FEDERICO
PULIDO ORTEGA

Profesor asociado de Ciencias de la Salud

Foto de FEDERICO

Foto de Orlando Immunology Center

Orlando Immunology Center

Orlando, Estados Unidos

Publicacions en col·laboració amb investigadors/es de Orlando Immunology Center (3)

2020

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial
The Lancet HIV, Vol. 7, Núm. 1, pp. e16-e26

2019

Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1
Antiviral Research, Vol. 170

2018

Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial
The Lancet HIV, Vol. 5, Núm. 5, pp. e211-e220